Navigation Links
Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Company's Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
Date:12/5/2012

ibuting to greater health risks and a high risk for mortality.

Many depressed patients are not correctly diagnosed and may receive no treatment at all.  Many other MDD patients who are treated do not achieve a full remission of their symptoms despite treatment.  In the NIMH sponsored STAR*D study (Sequenced Treatment Alternatives to Relieve Depression), only 36.8% of patients achieved remission with citalopram, a first-line antidepressant treatment in the sequence.  In fact, several other studies have also shown that less than 50% of treated MDD patients achieve more than a 50% reduction of their symptoms.  Some MDD patients appear to be resistant to antidepressant treatment.  Treatment resistant depression (TRD) is defined as the failure to fully respond to an antidepressant treatment despite having had an adequate dose and duration of treatment.  Despite the availability of many new therapeutic agents in recent decades, these medications have revealed issues related to limited efficacy and tolerability.  Currently available antidepressants are associated with adverse events, such as gastrointestinal symptoms, agitation, and sexual dysfunction that may affect treatment compliance.

About BrainCells Inc.

BrainCells Inc. is a clinical stage company that is developing novel therapies for the treatment of central nervous system (CNS) diseases based on the principal of blocking or antagonizing select metabotropic glutamate receptors (mGluR). Glutamate, an amino acid, functions as a neurotransmitter and glutamate receptors are implicated in a number of CNS diseases due to their central role in excitation of neural cells. BrainCells, in conjunction with its partner Taisho Pharmaceutical Co., Ltd., has pursued the development of a novel mGluR2/3 antagonist, BCI-632.  The compound and its prodrug, BCI-838, have been extensively studied in preclinical models suggesting broad therapeutic potential in the treatment
'/>"/>

SOURCE BrainCells Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tria Beauty, Inc. Announces Partnership with Jenny McCarthy
2. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
3. UBM Canon Announces its New Medical Technology Seminar Series
4. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
5. Perrigo Company Announces The Appointment Of Industry Veteran To Executive Vice President And General Manager, Rx
6. Ultra Clean Announces Participation in the Midtown CAP Summit Investor Conference
7. MetaStat Announces Presentations at the 2012 San Antonio Breast Cancer Symposium
8. Young Innovations Announces Definitive Agreement to be Acquired by Linden Capital Partners
9. ObeTherapy Announces the Publication of Results Obtained with one of its Lead Compounds on a New Target for the Treatment of Obesity and Type II Diabetes
10. GDS International Announces "Industry Leader of the Year" Award at its Fourth Annual European Pharmaceutical Drug Discovery Summit
11. Elbit Imaging Ltd. Announces InSightecs ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of Neurological Disorders in the Brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Yesterday, former Congressman Patrick Kennedy ... facility. Rep. Kennedy and Dick Moberg ... research in neurological disease and treatment. ... Garen Staglin , created One Mind, a ... that will radically accelerate the development and implementation ...
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the ... direct oral once-daily Factor Xa inhibitor, significantly reduced the ... or hip arthroplasty, when compared to enoxaparin. Patients receiving ... deep vein thrombosis (DVT) and pulmonary embolism (PE) than ...
... /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX ), ... outsourcing company with operations in China and the United ... Science and Chemistry Awards, held on December 12, 2011 ... theme of this year,s awards was Disease Biology. Guowei ...
Cached Medicine Technology:Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 2Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 3Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 4Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery 5WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards 2WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards 3
(Date:7/13/2014)... ability to identify odors might indicate the development ... of the eye could indicate the build-up of ... brain, according to the results of four research ... Conference 2014 (AAIC 2014) in Copenhagen. , In ... identify odors was significantly associated with loss of ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 A ... Wright & Schulte LLC to provide consumers with the ... sometimes accompany use of the blood-thinning medication, as well ... pending in courts around the country. The law ... who may have suffered from life-threatening internal bleeding and ...
(Date:7/13/2014)... Palatine, Illinois (PRWEB) July 13, 2014 Hope ... facilitating a monthly grief support group at the Tamarack Senior ... will be held at 10:30 A.M. on the 3rd Wednesdays ... July 16th, 2014 at the Tamarack Community located at 55 ... to all bereaved individuals and there is no cost for ...
(Date:7/13/2014)... Seattle, Wa (PRWEB) July 13, 2014 ... updated by Vkool.com, this is a comprehensive guide that ... to deal with KP (keratosis pilaris). This ...     Chapter 1: What Is Keratosis Pilaris? ,     Chapter ... Do I Know If I Have KP? , ...
(Date:7/12/2014)... Recently, Fadhits.com, a well-known wedding dress manufacturer and retailer, ... dresses to its product line. In addition, the company ... wants to bring more benefits for its loyal fans. ... prices, up to 72% off. , As a leader in ... online shop is a good place for ladies who want ...
Breaking Medicine News(10 mins):Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2
... Experimental use of cisplatin no better than standard treatment, ... -- Compared to the standard treatment regimen for anal ... before other treatments didn,t improve disease-free survival and resulted ... U.S. study. , Currently, the preferred primary therapy for ...
... they need, but sickest still going without, study finds , , ... benefit has resulted in some improvements for seniors but no ... report finds that Medicare beneficiaries are less likely to forego ... the sickest patients are still skipping meds due to burdensome ...
... For the first time, researchers have peered deeply at the ... angiopathy (CAA) -- a disease thought to cause stroke and ... protein molecule that is key to the formation of plaques ... chemist Christopher Jaroniec and his colleagues report their results this ...
... ,Muslims Care, campaign, WASHINGTON, April 22 On ... prominent national Islamic civil rights and,advocacy group will help ... G. Komen National Race for the Cure., The ... carry its own "Muslims Care" banner and many of ...
... GAINESVILLE, Fla. Spreading rumors and gossiping may not ... of this social type of bullying could linger into ... , In a study of 210 college students, ... relational victimization in adolescence and depression and anxiety in ...
... April 22 Perot Systems,Corporation (NYSE: PER ... agreement in which Perot Systems will implement advanced ... growth. Through this,agreement, Perot Systems will help SCA ... and 130 outpatient surgery centers and surgical,hospitals across ...
Cached Medicine News:Health News:New Anal Cancer Therapy Fails to Improve Outcomes 2Health News:Medicare Prescription Drug Benefit Shows Mixed Results 2Health News:Medicare Prescription Drug Benefit Shows Mixed Results 3Health News:First atomic-level look at a protein that causes brain disease 2Health News:Muslim Team to Take Part in D.C. 'Race for the Cure' 2Health News:Social form of bullying linked to depression, anxiety in adults 2Health News:Social form of bullying linked to depression, anxiety in adults 3Health News:Perot Systems and Surgical Care Affiliates Sign Five-Year Agreement to Implement Advanced Technology Solutions 2Health News:Perot Systems and Surgical Care Affiliates Sign Five-Year Agreement to Implement Advanced Technology Solutions 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: